SCHEMBL3124262

SCHEMBL3124262

CC(C)(C)OC(=O)N1CCC(NC(=O)c2cccc(C(=O)O)c2)CC1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 5/20 0.62
KDM4E B2RXH2 1/20 0.57
PKM P14618 1/20 0.57
HDAC4 P56524 1/20 0.53
EPHX1 P07099 1/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
PARP1 P09874 1/20 0.52
ALDH1A1 P00352 2/20 0.52
TSHR P16473 1/20 0.52
CCR8 P51685 1/20 0.51
GPR119 Q8TDV5 1/20 0.50
LMNA P02545 1/20 0.50
THRB P10828 1/20 0.50
CYP2C19 P33261 1/20 0.50
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12853559 0.91 USP30 (0.58) USP30KDM4EPKMHDAC4EPHX1
SCHEMBL13199301 0.90 KDM4E (0.68) USP30KDM4EPKMHDAC4EPHX1
SCHEMBL18050965 0.88 USP30 (0.58) USP30KDM4EPKMHDAC4EPHX1
SCHEMBL27633457 0.88 KMT2A (0.61) USP30HDAC4KMT2AMEN1ALDH1A1
SCHEMBL1711950 0.87 ALDH1A1 (0.69) USP30KDM4EPKMKMT2AMEN1
SCHEMBL18193492 0.86 USP30 (0.56) USP30KDM4EPKMHDAC4EPHX1
SCHEMBL22031528 0.85 USP30 (0.55) USP30KDM4EPKMHDAC4EPHX1
SCHEMBL17572113 0.85 ALDH1A1 (0.61) USP30KDM4EPKMKMT2AMEN1
SCHEMBL18051110 0.85 USP30 (0.55) USP30KDM4EPKMHDAC4EPHX1
SCHEMBL2957238 0.84 USP30 (0.54) USP30KDM4EPKMHDAC4EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
EP-2132178-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2009-12-16 EP disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 USP30 2887/4885KDM4E 3354/4885PKM 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.